Several factors are thought to influence the efficacy of HER2-targeted treatment directed at patients with ERBB2-mutated cancer, including cancer type, domain of the ERBB2 oncogenic variant, as well as concurring co-mutations and other genomic alterations. This evidence concerns the gene ERBB2 and cancer.